PatientsLikeMe ™

ALS
Join Now (It's free!)

Already a member? Log in

See More Treatments

See all treatments in the PatientsLikeMe system shared by patients just like you.


Brand Names: Mirapex, Mirapexin, Novo-Pramipexole, Pexola, r(+) pramipexole, Sifrol
See also: Research Study KNS-760704

What is Pramipexole? Pramipexole has similar effects of dopamine, a naturally occurring chemical in the body. Low levels of dopamine are associated with Parkinson's disease (PD). It is used to treat PD symptoms, such as stiffness, tremors, muscle spasms, and poor muscle control; also used to treat restless legs syndrome Read more...Click to read more below

See more information, including instructions, precautions, side effects, and interactions.


Reasons Taken

17 patients in the community are taking or have taken Pramipexole.

Reason # Patients Percentage of patients
Other 7 41%
Slow my ALS progress 5 29%
Fasciculations 2 11%
disease-related symptoms 2 11%
Restless Leg Syndrome 1 5%

Dosages

Based on the patients currently taking Pramipexole.

  0 mg none 0.25 mg day 0.375 mg day 0.75 mg day 1 mg day 1.5 mg day 2 other day 3 day 6 mL day 300 mg day
  1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 2 Number of Patients: 2  

Duration

How long current patients have been taking Pramipexole or how long patients were taking Pramipexole before stopping.

Currently taking Pramipexole

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
1
1
2
3

Stopped taking Pramipexole

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
1
1
1
Why Patients Stopped Taking Pramipexole (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1 33% Did not seem to work: 33%
Doctor's advice 1 33% Doctor's advice: 33%
Course of treatment ended 1 33% Course of treatment ended: 33%


Back to top